LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

LLY

947.62

-2.8%↓

JNJ

221.12

-0.62%↓

ABBV

201.14

-0.71%↓

UNH

379.44

+2.66%↑

AZN

182.32

+0.05%↑

Home・Lista de Ações・BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals Inc

Fechado

SetorSaúde

8.61 -3.15

Comprar Vender

Visão Geral

Variação de preço das ações

24h

Atual

Mín

8.55

Máximo

8.92

Indicadores-chave
By Trading Economics
Rendimento	349M 362M
Vendas	247M 407M
P/E Médio do Setor	7.603 49.8
EPS	1.121
Margem de lucro	89.106
Funcionários	435
EBITDA	234M 266M

Recomendações
By TipRanks
Recomendações	Compra Forte
Previsão para 12 meses	+152.02% upside

Dividendos
By Dow Jones
Próximos Ganhos	3 de ago. de 2026

Estatísticas de Mercado
By TradingEconomics
Capitalização de Mercado	465M 2.3B
Abertura anterior	11.76
Fecho anterior	8.61

Sentimento de Notícias

By Acuity

14%

86%

27 / 347 Ranking em Healthcare

BioCryst Pharmaceuticals Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

8 de mai. de 2026, 23:55 UTC

Ganhos

Review & Preview: Still Going Strong -- Barrons.com

8 de mai. de 2026, 20:50 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de mai. de 2026, 20:49 UTC

Ganhos

Why the Gap Between Chip and Software Stocks Keeps Getting Wider -- Barrons.com

8 de mai. de 2026, 20:25 UTC

Ganhos

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 de mai. de 2026, 19:43 UTC

Ganhos

Cencosud 1Q Rev $4.565B >CENCOSUD.SN

8 de mai. de 2026, 19:43 UTC

Ganhos

Cencosud 1Q Net $115M

8 de mai. de 2026, 19:20 UTC

Conversa de Mercado

Oil Futures End Session Higher, But Down on the Week -- Market Talk

8 de mai. de 2026, 19:18 UTC

Ganhos

Monster and Celsius Earnings Show Energy-Drink Fatigue Is Far From Over -- Barrons.com

8 de mai. de 2026, 19:16 UTC

Ganhos

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 de mai. de 2026, 19:08 UTC

Ganhos

This Mini Berkshire Hathaway Is a Buy. An Activist Investor Is Pushing to Break It Up. -- Barrons.com

8 de mai. de 2026, 19:05 UTC

Ganhos

Investors Feared Energy-Drink Fatigue. Monster and Celsius Earnings Offered Reassurance. -- Barrons.com

8 de mai. de 2026, 19:02 UTC

Conversa de Mercado

U.S. Natural Gas Futures Little Changed on Week -- Market Talk

8 de mai. de 2026, 18:51 UTC

Ganhos

Memory Stocks Continue to Surge. What's Driving Micron and Sandisk Higher. -- Barrons.com

8 de mai. de 2026, 18:49 UTC

Ganhos

These Stocks Are Today's Movers: Rocket Lab, Moderna, HubSpot, Nvidia, CoreWeave, Trade Desk, Cloudflare, Fluor, Akamai, IREN, and More -- Barrons.com

8 de mai. de 2026, 18:41 UTC

Ganhos

McDonald's Stock Rises on Earnings Beat. The Value Push Needs to Maintain Momentum. -- Barrons.com

8 de mai. de 2026, 17:38 UTC

Conversa de Mercado

U.S. Oil Rig Count Rises By 2 to 410 -- Market Talk

8 de mai. de 2026, 17:14 UTC

Ganhos

How High Gas Prices Need to Rise to Boost Electric Vehicle Sales -- Barrons.com

8 de mai. de 2026, 17:04 UTC

Conversa de Mercado

Zcash Caps Off Parabolic Week -- Market Talk

8 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Tech, Media & Telecom Roundup: Market Talk

8 de mai. de 2026, 16:20 UTC

Conversa de Mercado

Basic Materials Roundup: Market Talk

8 de mai. de 2026, 16:15 UTC

Conversa de Mercado

Global Commodities Roundup: Market Talk

8 de mai. de 2026, 15:39 UTC

Conversa de Mercado

Gold Seen Transitioning Away From 'Corrective Phase' -- Market Talk

8 de mai. de 2026, 15:39 UTC

Conversa de Mercado

Global Forex and Fixed Income Roundup: Market Talk

8 de mai. de 2026, 15:39 UTC

Conversa de Mercado

Canada's Job Market Sees Worst Start in Years -- Market Talk

8 de mai. de 2026, 15:36 UTC

Conversa de Mercado

A Jump in Canada's Jobless Rate May Turn Out to Be a Blip -- Market Talk

8 de mai. de 2026, 15:20 UTC

Conversa de Mercado

'Altcoin Season' Indicator on the Rise -- Market Talk

8 de mai. de 2026, 15:20 UTC

Conversa de Mercado

Ganhos

Enbridge Gas Pipelines, Distribution Units Drive 1Q Beat -- Market Talk

8 de mai. de 2026, 15:05 UTC

Conversa de Mercado

Bitcoin Slips Back Below the $80k Mark -- Market Talk

8 de mai. de 2026, 14:42 UTC

Conversa de Mercado

Tough Times for Canadian Teenagers Looking for Work -- Market Talk

8 de mai. de 2026, 14:39 UTC

Conversa de Mercado

Canadian Labor Market Suggests Persistent Higher Inflation Unlikely -- Market Talk

Comparação entre Pares

Variação de preço

BioCryst Pharmaceuticals Inc Previsão

Preço-alvo

By TipRanks

152.02% parte superior

Previsão para 12 meses

Média 22.43 USD 152.02%

Máximo 32 USD

Mínimo 13 USD

Com base em 8 analistas de Wall Street que oferecem metas de preço de 12 meses para BioCryst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

8 ratings

Comprar

Manter

Vender

Com base em 8 analistas que deram avaliações de ações para BioCryst Pharmaceuticals Inc - Dist nos últimos 3 meses.

Sentimento

By Acuity

27 / 347 Ranking em Saúde

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

Sobre BioCryst Pharmaceuticals Inc

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.